Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.56 USD

18.56
5,133,286

+0.17 (0.92%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $18.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Teva Migraine Candidate Succeeds in Second Phase III Study

Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.

    Regeneron Announces Positive Data on Carcinoma Candidate

    Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

      Teva's Migraine Candidate TEV-48125 Positive in Phase III

      Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).

        Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

        Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

          Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA

          Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.

            Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

            Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.

              Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint

              Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies

                Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls

                Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.

                  Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

                  Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

                    Teva (TEVA) Q1 Earnings In-Line, Sales Miss, Shares Up

                    Teva???s first quarter earnings (including equity compensation expenses), came in at $1.03 per share, in-line with the consensus estimate.

                      Swarup Gupta headshot

                      Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?

                      Mylan and Teva are scheduled to report on May 10 and May 11

                        Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View

                        Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.

                          Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?

                          Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11

                            Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?

                            Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.

                              Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug

                              Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).

                                Allergan (AGN) Presents Mixed Depression Data on Botox

                                Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).

                                  Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline

                                  Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.

                                    Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst

                                    Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.

                                      5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

                                      Lily carries a Zacks Rank #2 (Buy).

                                        Teva's Austedo Gets FDA Nod for Huntington Disease Treatment

                                        Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that the FDA has approved its investigational drug, Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington disease (HD).

                                          Allergan Acne Candidate Meets Endpoints in Phase III Studies

                                          Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline

                                            Teva Pharma Denies Rumors of Global Workforce Reduction

                                            According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.

                                              Allergan's Restasis Now Available in Multidose Bottle in U.S.

                                              Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.

                                                Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod

                                                Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.

                                                  Nektar's Pain Drug Positive in Phase III Study; Shares Gain

                                                  Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.